Allison Naumovski

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Left Ventricular

Advanced Non Small Cell Lung Cancer

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)